Core Viewpoint - Connect Biopharma is advancing its clinical development of rademikibart, a novel biologic treatment for asthma and COPD, with positive Phase 2 trial results and a strong financial position to support ongoing studies and operations [1][2][3]. Clinical Development - The company initiated Phase 2 Seabreeze STAT studies for rademikibart as an adjunct treatment for acute exacerbations in asthma and COPD, with topline data expected in the first half of 2026 [1][3]. - A positive Type C meeting with the FDA was completed, aligning on the Phase 2 study protocols [3]. - Rademikibart showed significant improvements in lung function, with a mean difference from placebo in forced expiratory volume of +420 mL in patients with eosinophilic-driven asthma after 24 weeks [3]. Financial Performance - For the three months ended March 31, 2025, the company reported a net loss of $10.3 million, or $0.19 per share, compared to a net loss of $8.7 million, or $0.16 per share, for the same period in 2024 [8][13]. - Research and Development expenses decreased to $6.6 million from $8.7 million year-over-year, while General and Administrative expenses increased to $4.8 million from $4.0 million [8][13]. - As of March 31, 2025, cash, cash equivalents, and short-term investments totaled $84.0 million, expected to fund operations into 2027 [8][15]. Upcoming Events - The company has four posters accepted for presentation at the American Thoracic Society (ATS) 2025 International Conference, supporting the development of rademikibart for patients with moderate-to-severe asthma or COPD experiencing acute exacerbations [2][3][8].